Moleculin Biotech
MBRX
24 hedge funds and large institutions have $413K invested in Moleculin Biotech in 2025 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 5 closing their positions.
400% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 1
250% more capital invested
Capital invested by funds: $118K → $413K (+$295K)
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
14% more funds holding
Funds holding: 21 → 24 (+3)
0.05% less ownership
Funds ownership: 0.11% → 0.06% (-0.05%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$113K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$97.6K |
| 3 |
HF
HRT Financial
New York
|
+$62.2K |
| 4 |
IC
IEQ Capital
Foster City,
California
|
+$19.7K |
| 5 |
WDG
Wealth Dimensions Group
Cincinnati,
Ohio
|
+$10.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
-$25.7K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$22.4K |
| 3 |
VF
Virtu Financial
New York
|
-$18K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$2.17K |
| 5 |
SHIM
Stone House Investment Management
Tunkhannock,
Pennsylvania
|
-$996 |
MBRX Hedge Fund Activity: Q3 2025 in Review
24 of the 7,629 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q3 2025, worth a combined $413K — up 250% from $118K a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new MBRX positions and 5 closed out — a net gain of 3 holders — while 5 added to existing stakes and 1 trimmed.
The largest buyer was Vanguard Group, adding an estimated $113K. The largest seller was Citigroup, exiting entirely with an estimated $25.7K sold.
- 24 institutional investors held Moleculin Biotech (MBRX) as of Q3 2025, up from 21 in Q2 2025.
- Funds reported $413K of Moleculin Biotech stock for Q3 2025, up 250% quarter-over-quarter.
- 8 funds opened new Moleculin Biotech positions in Q3 2025 and 5 closed out, a net change of +3 holders.
- The largest Moleculin Biotech buyer in Q3 2025 was Vanguard Group, an estimated $113K added.
- The largest Moleculin Biotech seller in Q3 2025 was Citigroup, an estimated $25.7K sold.
Based on aggregated 13F filings for Q3 2025.